All posts by medical

Cell Biology

Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy…

SAN DIEGO, April 1, 2020 /PRNewswire/ -- Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

"Our mission at Aspen Neuroscience is to develop a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson disease," said Dr. Howard Federoff, Chief Executive Officer of Aspen Neuroscience. "We are dedicated to using a person's own cells for replacement therapy and bringing best-in-class treatments to people suffering from Parkinson disease as rapidly as possible."

"We are impressed by the progress Aspen has made to date against its goals to develop innovative therapies to treat Parkinson disease and encouraged by the broader investment community's support of the company," said Jonathan Silverstein, Managing Partner of OrbiMed.

Aspen's lead product, ANPD001, is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic forms of Parkinson disease. Aspen's second product, ANPD002, combines gene correction and autologous neuron therapy for the treatment of genetic forms of Parkinson disease. Aspen leverages proprietary AI-based genomics tools for comprehensive quality control which allows for a reduction in the time and cost of the manufacturing process required to produce a safe, reproducible, and personalized cell therapy.

The Series A funding will support the completion of all remaining IND-enabling studies and FDA submission of the IND relating to Aspen's lead product (ANPD001), as well as the recruitment and screening of a trial-ready cohort of persons with Parkinson disease and the manufacture of their cells for the lead product. Additionally, the capital will allow the company to obtain meaningful data from the Phase 1 clinical study to show evidence of biological effect of the therapy and lay the foundation for the Phase 2 multi-center randomized controlled trial. The financing will also support the continued R&D pipeline which includes autologous gene-corrected dopamine neurons for heritable forms of Parkinson disease risk (ANPD002) and programs that extend beyond dopamine neurons and explore the treatment of diseases marked by neuroinflammation.

About Aspen NeuroscienceAspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visit http://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-announces-70-million-series-a-financing-led-by-orbimed-to-advance-development-of-the-first-autologous-neuron-replacement-therapy-to-treat-parkinson-disease-301033098.html

SOURCE Aspen Neuroscience

The rest is here:
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy...

Cell Biology

Scailyte Announces Its New Advisory Board, Composed of World Leading Clinicians and Scientists – PharmiWeb.com

SURSEE, Switzerland, March 31, 2020 (Newswire.com) - Scailyte is an ETH Zurichspin-off and Top 100 Swiss Startup applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data. Over the past threeyears, it has established ScaiVision, a proprietary data analytics platform for clinical research, which enables it to achieve groundbreaking discoveries in multiple disease areas. Scailyte has validated its approach by discovering its first single-cell biomarker for the detection of skin T-cell lymphoma, which it iscurrently translating into an in vitro diagnostics application that will radically improve the diagnosis and survival chances for thousands of patients suffering from this disease. Scailyteisscaling up its efforts by applying itsbiomarker discovery approach for multiple indications in oncology and womens health. In order to strengthen Scailytes discovery potential and provide strategic guidance, ithasappointed a scientific advisory board consisting of world-leading clinicians and scientists. The scientific advisory board is being led by Scailyte's co-founder, Professor Dr. Manfred Claasen.

Scailytes mission is to provide better healthcare and transform diagnostics, with particular focus on diseases with high unmet diagnostic need. With the rise of novel single-cell technologies, we are now in the unique position to leverage the potential of high dimensional single-cell data, and Scailyte is at the forefront of turning this potential into clinical applications, says Prof. Claassen

Prof. Dr. Manfred Claassen has been recently appointed as full professor in Clinical Bioinformatics at the University Hospital of Tubingen,with a focus on machine learning for single-cell biology and precision medicine. Prof. Claassen is an alumnus of the University of Tubingen and obtained his PhD from ETH Zurich. He did postdoctoral studies at Stanford University, where he pioneered research in single-cell data analysis and subsequently started his independent research group at ETH Zurich. This activity resulted in the key developments of an algorithm that paved the way for Scailytes innovative implementation of deep learning approaches for cell identity biomarker discovery.

Prof. Dr. Emmanuella Guenova is a dermatologist, specialist in cutaneous lymphoma and laboratory diagnostics of skin diseases, and appointed professor at the Faculty of Biology and Medicine of the University of Lausanne. She is a senior physician-scientist, leading the specialized cutaneous lymphoma clinic at the Department of Dermatology of the Lausanne University Hospital (CHUV). Prof. Guenova is supporting Scailyte as a clinical advisor and principal investigator in its clinical development program for cutaneous T-cell lymphoma.

Prof. Dr. Michael Mueller is a renowned gynecologist and gynecological oncologist, and managing director of the Women's Health Clinic at the University Hospital of Bern (Inselspital). Prof. Mueller is supporting Scailyte as a clinical advisor and expert in endometriosis and womens health.

Prof. Dr. Tomas Kalina is a physician and a cytometry expert currently leading a research group focused on disorders of adaptive immunity at the Charles University in Prague. Professor Kalina is supporting Scailyte as a clinical diagnostic advisor with his expertise in cytometry standardization.

Prof. Dr. Petter Brodin is a pioneer in single-cell analysis and is advising Scailyte in immunology and the application of single-cell technologies for clinical research. Prof. Brodin is based at the Karolinska Institute in Sweden and heads a research group that focuses on systems level analyses of the human immune system. Prof. Brodin is a consultant pediatrician working at the Karolinska University Hospital

Dr. Michael Stadler received training in immunology and bioinformatics from the Universities of Lausanne and Geneva. He is a scientific advisor supporting Scailytes with the development of itsdata analytics platform.After postdoctoral studies in Bern and at the Massachusetts Institute of Technology (MIT), he joined the Friedrich Miescher Institute for Biomedical Research (FMI) Basel, where he is a staff scientist and leads the computational biology group.

About Scailyte

Scailyte AG is a data-driven biomarker discovery company, founded in Luzern, Switzerland in 2017. The ETH Spin-off is using cutting edge technologies within the single-cell space and a proprietary biomarker discovery platform to develop clinical diagnostic applications in oncology and womens health. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

http://www.scailyte.com

Scailyte and ScaiVision are registered trademarks proprietary to Scailyte AG.

The rest is here:
Scailyte Announces Its New Advisory Board, Composed of World Leading Clinicians and Scientists - PharmiWeb.com

Neuroscience

Newly-Discovered Gene Mutation Improves Cognitive Flexibility in Mice | Biology, Neuroscience – Sci-News.com

A team of U.S. researchers has discovered a genetic mutation that improves cognitive flexibility in mice.

Hu et al reveal a novel mechanism regulating reversal learning and provide potential targets for the treatment of neuropsychiatric disorders characterized by cognitive inflexibility. Image credit: Alexas Fotos.

Electrical signals stimulate chemical messengers that jump from neuron to neuron.

A gene called KCND2 codes for a protein that regulates potassium channels, which control electrical signals that travel along neurons.

Dr. Dax Hoffman from NIHs Eunice Kennedy Shriver National Institute of Child Health and Human Development and colleagues found that altering a single base pair in the KCND2 gene enhanced the ability of the protein to dampen nerve impulses.

Mice with this mutation performed better than mice without the mutation in a cognitive task.

The task involved finding and swimming to a slightly submerged platform that had been moved to a new location.

Mice with the mutation found the relocated platform much faster than their counterparts without the mutation.

The scientists now plan to investigate whether the mutation will affect neural networks in the animals brains.

Studying the gene and its protein may ultimately lead to insights on the nature of cognitive flexibility in people, they said.

It also may help improve understanding of epilepsy, schizophrenia, Fragile X syndrome, and autism spectrum disorder, which all have been associated with other mutations in KCND2.

The findings are published in the journal Nature Communications.

_____

J. Hu et al. 2020. Activity-dependent isomerization of Kv4.2 by Pin1 regulates cognitive flexibility. Nat Commun 11, 1567; doi: 10.1038/s41467-020-15390-x

Read more here:
Newly-Discovered Gene Mutation Improves Cognitive Flexibility in Mice | Biology, Neuroscience - Sci-News.com

Neuroscience

Special Issue: The Year in Cognitive Neuroscience (vol 1464) – The New York Academy of Sciences

REVIEWS

The present and future use of functional nearinfrared spectroscopy (fNIRS) for cognitive neuroscience

Paola Pinti, Ilias Tachtsidis, Antonia Hamilton, Joy Hirsch, Clarisse Aichelburg, Sam Gilbert, Paul W. Burgess

Models, movements, and minds: bridging the gap between decision making and action

Nathan J. Wispinski, Jason P. Gallivan, Craig S. Chapman

Recent evidence that attention is necessary, but not sufficient, for conscious perception

Sean Noah, George R. Mangun

Between persistently active and activitysilent frameworks: novel vistas on the cellular basis of working memory

Jan Kamiski, Ueli Rutishauser

Challenging the neurobiological link between number sense and symbolic numerical abilities

Eric D. Wilkey, Daniel Ansari

Musical anhedonia and rewards of music listening: current advances and a proposed model

Amy M. Belfi, Psyche Loui

The intersection between the oculomotor and hippocampal memory systems: empirical developments and clinical implications

Jennifer D. Ryan, Kelly Shen, ZhongXu Liu

Allocentric representations for target memory and reaching in human cortex

Ying Chen, J. Douglas Crawford

Ovarian hormones: a long overlooked but critical contributor to cognitive brain structures and function

Adriene M. Beltz, Jason S. Moser

The importance of diversity in cognitive neuroscience

Vonetta M. Dotson, Audrey Duarte

A new look at the cognitive neuroscience of video game play

Gillian Dale, Augustin Joessel, Daphne Bavelier, C. Shawn Green

Inhibition in selective attention

Dirk van Moorselaar, Heleen A. Slagter

Beyond the feedforward sweep: feedback computations in the visual cortex

Gabriel Kreiman, Thomas Serre

Evaluating the neurophysiological evidence for predictive processing as a model of perception

Kevin S. Walsh, David P. McGovern, Andy Clark, Redmond G. O'Connell

View post:
Special Issue: The Year in Cognitive Neuroscience (vol 1464) - The New York Academy of Sciences

Neuroscience

Tracking the Spread of Tau Through the Brain – Technology Networks

In the fight against neurodegenerative diseases such as frontotemporal dementia, Alzheimer's and Chronic Traumatic Encephalopathy, the tau protein is a major culprit. Found abundantly in our brain cells, tau is normally a team player it maintains structure and stability within neurons, and it helps with transport of nutrients from one part of the cell to another.All that changes when tau misfolds. It becomes sticky and insoluble, aggregating and forming neurofibrillary tangles within neurons, disrupting their function and ultimately killing them. Worse, it probably can take relatively few misfolded tau proteins from one cell to turn its neighbors into malfunctioning, dying brain cells.

"This abnormal form of tau starts to spread from cell to cell," said UC Santa Barbara neuroscientist Kenneth S. Kosik. "It's reminiscent of a serious problem that's known in biology, called prion diseases, such as mad cow disease."

Importantly, unlike true prion diseases, which are spread by contact with infected tissue or bodily fluid, prion-like diseases such as frontotemporal dementia and other tauopathies aren't contagious they can't be spread from person to person or by coming into contact with infected tissue. However, the replication is eerily familiar: A misfolded tau protein gets out of a cell and gets taken up by a normal neighboring cell. It then acts as a template in that cell, Kosik explained, which subsequently produces misfolded tau. Over and over again, the cells produce and secrete the toxic knockoff version of tau until whole regions of the brain are affected, which over time will rob a person of their cognitive and physical functions.

What if the spread could be contained? If caught early enough, controlling the proliferation of pathological tau could keep the neurodegenerative disease from progressing, and give the patient a shot at a normal life. But in order to do that, scientists first have to understand how the protein gets around.

Kosik and his team have uncovered one such mechanism by which tau travels from neuron to neuron. Not only does it shed light on the extensively studied but rather poorly understood tau propagation in neurodegenerative disease, it hints at a way to control the spread of pathological tau.

"The discovery of a mechanism by which tau transits from cell to cell provides a clue that will open up a deep structural approach to the design molecules that can prevent tau spread," said Kosik, who is the Harriman Professor of Neuroscience Research in UC Santa Barbara's Department of Molecular, Cellular, and Developmental Biology.

The major player in this mechanism of uptake and spread, it turns out, is the low-density lipoprotein called LRP1 (low density lipoprotein receptor-related protein 1). It's located on the brain cell membrane and is involved is several biological processes, among them helping the neuron take in cholesterol, which is used as part of cellular structure.

LRP1, the researchers discovered, takes up tau in neighboring cells after it escapes from a cell into the extracellular space. One of several low density lipoprotein receptors, LRP1 was singled out by process of elimination: By systematically inhibiting the expression of each of the members of this family via CRISPRi technology, and exposing them to tau, the researchers determined that genetic silencing of LRP1 effectively inhibited tau uptake.

"This protein is an interesting one in its own right because it's a little bit like an extracellular trash can," Kosik said. "It doesn't just pick up tau; if there's other rubbish out there, it also picks it up."

But what about tau is LRP1 recognizing? Digging deeper, the scientists found that a stretch of the amino acid lysine on the tau protein acts as kind of the secret handshake that opens the doors to the neuron.

"So these are all clues," Kosik said.Stopping the Spread"Since our cellular work showed that tau can interact with the cell-surface receptor LRP1 and that this causes tau's endocytosis, our hypothesis was that if we reduce LRP1 expression in the mice we should reduce the ability for neighboring neurons to take up tau," explained the study's lead author, postdoctoral researcher Jennifer Rauch.

To back their in-vitro studies, the researchers injected tau into mice, some of which had their LRP1 genes downregulated by a LRP1 suppressor RNA. The tau proteins were bound by a small string of amino acids to a green fluorescent protein to help the scientists observe tau after it was injected.

"As soon as this construct is in a cell, the amino acid connector gets cut, and the fluorescent protein and tau separate from each other," Kosik explained. What they found was that in the animals with normal LRP1, the tau had a tendency to spread; in the LRP1-suppressed mice, the protein stayed put, greatly reducing the likelihood that it would be taken up and replicated by other, normal neurons. "This is the first time we've seen the complete obliteration of tau spread," he said.

"When we reduce LRP1 expression, we see reduced tau spread in the animals," said Rauch, who has previously worked on the role of heparan sulphate proteoglycans on tau uptake. She pointed out a recent study that included Kosik and graduate student Juliana Acost-Uribe that described a patient with a severe genetic form of early-onset Alzheimers's but was spared getting the disease due to a second mutation that appeared to prevent tau spread. The team is keen to learn how this patient's second mutation might prevent tau spread possibly by interacting with LRP1.

"Next," Rauch said, "we are focusing on trying to decipher the interface of the tau-LRP1 interaction and understand if this could be a drug-able target."ReferenceRauch et al. (2020) LRP1 is a master regulator of tau uptake and spread. Nature. DOI: https://doi.org/10.1038/s41586-020-2156-5

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View post:
Tracking the Spread of Tau Through the Brain - Technology Networks

Neuroscience

Neuroscience Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| GE Healthcare, Siemens Healthineers, Noldus…

Complete study of the global Neuroscience market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Neuroscience industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Neuroscience production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Neuroscience market include _ GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex Bioscience, Thomas RECORDING GmbH, Blackrock Microsystems, Tucker-Davis Technologies, Plexon, Phoenix Technology Group, NeuroNexus, Alpha Omega Neuroscience Breakdown Data by Type

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1437954/global-neuroscience-market

Segmental Analysis

The report has classified the global Neuroscience industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Neuroscience manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Neuroscience industry.

Global Neuroscience Market Segment By Type:

, Whole Brain Imaging, Neuro-Microscopy, Electrophysiology Technologies, Neuro-Cellular Manipulation, Stereotaxic Surgeries, Animal Behavior, Other, Whole Brain Imaging, Neuro-Microscopy, and Electrophysiology Technologies are the top three types of neuroscience, with a combined market share of 62% Neuroscience Breakdown Data by Application,

Global Neuroscience Market Segment By Application:

Hospitals, Diagnostic Laboratories, Research Institutes, Other, Neuroscience is applied mostly in the hospital with a market share of 47%. It is followed by Research Institutes and Diagnostic Laboratories

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Neuroscience industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Neuroscience market include _ GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex Bioscience, Thomas RECORDING GmbH, Blackrock Microsystems, Tucker-Davis Technologies, Plexon, Phoenix Technology Group, NeuroNexus, Alpha Omega Neuroscience Breakdown Data by Type

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1437954/global-neuroscience-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Neuroscience Revenue1.4 Market Analysis by Type1.4.1 Global Neuroscience Market Size Growth Rate by Type: 2020 VS 20261.4.2 Whole Brain Imaging1.4.3 Neuro-Microscopy1.4.4 Electrophysiology Technologies1.4.5 Neuro-Cellular Manipulation1.4.6 Stereotaxic Surgeries1.4.7 Animal Behavior1.4.8 Other1.5 Market by Application1.5.1 Global Neuroscience Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Diagnostic Laboratories1.5.4 Research Institutes1.5.5 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Neuroscience Market Perspective (2015-2026)2.2 Neuroscience Growth Trends by Regions2.2.1 Neuroscience Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Neuroscience Historic Market Share by Regions (2015-2020)2.2.3 Neuroscience Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Neuroscience Market Growth Strategy2.3.6 Primary Interviews with Key Neuroscience Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Neuroscience Players by Market Size3.1.1 Global Top Neuroscience Players by Revenue (2015-2020)3.1.2 Global Neuroscience Revenue Market Share by Players (2015-2020)3.1.3 Global Neuroscience Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Neuroscience Market Concentration Ratio3.2.1 Global Neuroscience Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Neuroscience Revenue in 20193.3 Neuroscience Key Players Head office and Area Served3.4 Key Players Neuroscience Product Solution and Service3.5 Date of Enter into Neuroscience Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Neuroscience Historic Market Size by Type (2015-2020)4.2 Global Neuroscience Forecasted Market Size by Type (2021-2026) 5 Neuroscience Breakdown Data by Application (2015-2026)5.1 Global Neuroscience Market Size by Application (2015-2020)5.2 Global Neuroscience Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Neuroscience Market Size (2015-2020)6.2 Neuroscience Key Players in North America (2019-2020)6.3 North America Neuroscience Market Size by Type (2015-2020)6.4 North America Neuroscience Market Size by Application (2015-2020) 7 Europe7.1 Europe Neuroscience Market Size (2015-2020)7.2 Neuroscience Key Players in Europe (2019-2020)7.3 Europe Neuroscience Market Size by Type (2015-2020)7.4 Europe Neuroscience Market Size by Application (2015-2020)(2015-2020) (2015-2020) (2015-2020) (2015-2020) 8Key Players Profiles8.1 GE Healthcare8.1.1 GE Healthcare Company Details8.1.2 GE Healthcare Business Overview and Its Total Revenue8.1.3 GE Healthcare Neuroscience Introduction8.1.4 GE Healthcare Revenue in Neuroscience Business (2015-2020))8.1.5 GE Healthcare Recent Development8.2 Siemens Healthineers8.2.1 Siemens Healthineers Company Details8.2.2 Siemens Healthineers Business Overview and Its Total Revenue8.2.3 Siemens Healthineers Neuroscience Introduction8.2.4 Siemens Healthineers Revenue in Neuroscience Business (2015-2020)8.2.5 Siemens Healthineers Recent Development8.3 Noldus Information Technology8.3.1 Noldus Information Technology Company Details8.3.2 Noldus Information Technology Business Overview and Its Total Revenue8.3.3 Noldus Information Technology Neuroscience Introduction8.3.4 Noldus Information Technology Revenue in Neuroscience Business (2015-2020)8.3.5 Noldus Information Technology Recent Development8.4 Mightex Bioscience8.4.1 Mightex Bioscience Company Details8.4.2 Mightex Bioscience Business Overview and Its Total Revenue8.4.3 Mightex Bioscience Neuroscience Introduction8.4.4 Mightex Bioscience Revenue in Neuroscience Business (2015-2020)8.4.5 Mightex Bioscience Recent Development8.5 Thomas RECORDING GmbH8.5.1 Thomas RECORDING GmbH Company Details8.5.2 Thomas RECORDING GmbH Business Overview and Its Total Revenue8.5.3 Thomas RECORDING GmbH Neuroscience Introduction8.5.4 Thomas RECORDING GmbH Revenue in Neuroscience Business (2015-2020)8.5.5 Thomas RECORDING GmbH Recent Development8.6 Blackrock Microsystems8.6.1 Blackrock Microsystems Company Details8.6.2 Blackrock Microsystems Business Overview and Its Total Revenue8.6.3 Blackrock Microsystems Neuroscience Introduction8.6.4 Blackrock Microsystems Revenue in Neuroscience Business (2015-2020)8.6.5 Blackrock Microsystems Recent Development8.7 Tucker-Davis Technologies8.7.1 Tucker-Davis Technologies Company Details8.7.2 Tucker-Davis Technologies Business Overview and Its Total Revenue8.7.3 Tucker-Davis Technologies Neuroscience Introduction8.7.4 Tucker-Davis Technologies Revenue in Neuroscience Business (2015-2020)8.7.5 Tucker-Davis Technologies Recent Development8.8 Plexon8.8.1 Plexon Company Details8.8.2 Plexon Business Overview and Its Total Revenue8.8.3 Plexon Neuroscience Introduction8.8.4 Plexon Revenue in Neuroscience Business (2015-2020)8.8.5 Plexon Recent Development8.9 Phoenix Technology Group8.9.1 Phoenix Technology Group Company Details8.9.2 Phoenix Technology Group Business Overview and Its Total Revenue8.9.3 Phoenix Technology Group Neuroscience Introduction8.9.4 Phoenix Technology Group Revenue in Neuroscience Business (2015-2020)8.9.5 Phoenix Technology Group Recent Development8.10 NeuroNexus8.10.1 NeuroNexus Company Details8.10.2 NeuroNexus Business Overview and Its Total Revenue8.10.3 NeuroNexus Neuroscience Introduction8.10.4 NeuroNexus Revenue in Neuroscience Business (2015-2020)8.10.5 NeuroNexus Recent Development8.11 Alpha Omega10.11.1 Alpha Omega Company Details10.11.2 Alpha Omega Business Overview and Its Total Revenue10.11.3 Alpha Omega Neuroscience Introduction10.11.4 Alpha Omega Revenue in Neuroscience Business (2015-2020)10.11.5 Alpha Omega Recent Development 9Analysts Viewpoints/Conclusions 10Appendix10.1 Research Methodology10.1.1 Methodology/Research Approach10.1.2 Data Source10.2 Disclaimer10.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continued here:
Neuroscience Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| GE Healthcare, Siemens Healthineers, Noldus...

Neuroscience

Woman With COVID-19 May Have Developed Rare Brain Disease From Coronavirus, Her Detroit Doctors Say – Newsweek

A woman in Detroit is thought to be the first person to have brain damage linked to COVID-19, according to the doctors who treated her. The clinicians stressed it is not clear if the rare condition was caused by the new coronavirus, but said it was important for doctors to be aware of it as a possible complication.

The case of the unidentified 58-year-old COVID-19 patient diagnosed with a rare form of brain damage known as acute necrotizing hemorrhagic encephalopathy was detailed in the journal Radiology. The condition has been linked with other viral infections in the past but not yet COVID-19, the authors said.

Dr. Elissa Fory, a neurologist at Detroit's Henry Ford health system who helped to diagnose the woman, said in a statement the patient had experienced a fever, cough and muscle aches. She was rushed by ambulance to an emergency room on March 19, after becoming confused, lethargic and disoriented.

According to the journal article, the woman tested positive for COVID-19, and negative for the flu. The team were unable to test the woman's cerebrospinal fluid for SARS-CoV-2, the virus that causes COVID-19 (not to be confused with the SARS virus).

MRI scans showed abnormal lesions in parts of the woman's brain associated with consciousness, sensation and memory function, the statement explained. "The 58-year-old female patient is hospitalized in serious condition," the health system said.

The authors of the paper explained acute necrotizing encephalopathy is a "rare complication" of viral infections such as the flu, particularly in children. It has been linked to cytokine storms, where the immune system dangerously overreacts. This can "result in blood-brain-barrier breakdown," they said.

Growing evidence suggests some COVID-19 patients might experience cytokine storms, according to the team.

Fory said: "This is significant for all providers to be aware of and looking out for in patients who present with an altered level of consciousness. We need to be thinking of how we're going to incorporate patients with severe neurological disease into our treatment paradigm.

"This complication is as devastating as severe lung disease."

As indicated in the map by Statista below, COVID-19 has spread to almost every country and territory in the world. According to Johns Hopkins University, almost 1 million cases have been confirmed worldwide, 47,522 people have died, and at least 195,929 have recovered. According to the CDC, common COVID-19 symptoms include a fever, cough, and shortness of breath.

Professor Neil Scolding of the U.K.'s University of Bristol Institute of Clinical Neurosciences, who did not work on the paper, told Newsweek: "This is the first reported case of severe brain inflammation related to COVID-19 and so is highly significant.

"We had suspected this kind of inflammation could occur, since it happensthough rarelywith conventional influenza virus infection, and with other viruses related to COVID-19."

Scolding said the study "serves as a valuable reminder to the medical community to look out for this complication."

Asked who might be most at risk of such a complication, Scolding said: "We don't know who will be most susceptible. With flu, it is children who are more likely to get this complicationbut children seem rather resistant to COVID-19, and the individual in this report is an adult."

Scolding stressed: "We do think it will remain a rather rare complication, and so I do not think people should start routinely looking out for confusion or other brain-related symptoms."

Professor Cris S. Constantinescu, of the Division of Clinical Neuroscience at the U.K.'s University of Nottingham Queen's Medical Centre, told Newsweek that while the case study describes a single report, it adds to the emerging evidence that SARS-cov-2 can affect the nervous system.

As the test to detect the virus in the cerebrospinal fluid could not be performed, "it is unclear whether the encephalitis was the direct effect of viral invasion" he said.

Constantinescu said it is "important" for people to look out for symptoms such as confusion as a potential COVID-19 symptom.

"In particular people with neurological diseases requiring immunosuppressive treatments such as multiple sclerosis or myasthenia gravis should be vigilant as they are at higher risk of infection, and have diminished immune responses to the infection.

"They should not always attribute new neurological symptoms [to] their underlying neurological disease. Also COVID-19 patients and carers should be aware of potential neurological problems," he said.

As the disease spreads, said Constantinescu, "we will become increasingly aware of neurological complications of COVID-19 and of the implications of COVD-19 infections in people with underlying neurological conditions. Even rare complications such as this one have great informative value."

Hygiene advice

Medical advice

Mask and glove usage

The rest is here:
Woman With COVID-19 May Have Developed Rare Brain Disease From Coronavirus, Her Detroit Doctors Say - Newsweek

Immunology

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines – PharmiWeb.com

INDIANAPOLISandOXFORD, England,March 31, 2020/PRNewswire/ --Eli Lilly and Company(NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.

"AsLillyseeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners," saidAjay Nirula, M.D., Ph.D., vice president of immunology atLilly. "Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets."

"We are excited to partner withLilly, one of the global leaders in the field of immunology, to pursue the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory diseases in the fast-emerging area of immunometabolism," saidNeil Weir, Ph.D.,chief executive officer of Sitryx. "This agreement is transformational for Sitryx and further validates the strength of our scientific expertise and that of our Founder network and the potential for Sitryx to become a leader in this field."

Under the terms of the agreement, Sitryx will receive an upfront payment of$50 millionandLillywill make a$10 millionequity investment in Sitryx. Sitryx will be eligible to receive potential development milestones up to$820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range. In return, Sitryx will grantLillyan exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects.Lillyand Sitryx will establish a 5-year research collaboration to support the development of the therapeutics, with Sitryx responsible for drug discovery, whileLillywill fund and manage the clinical development and commercial phase of the collaboration.

This transaction is subject to customary closing conditions. The transaction will be reflected inLilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change toLilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

About SitryxSitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism;Houman Ashrafian,Luke O'Neill,Jonathan Powell,Jeff Rathmell,Michael RosenblumandPaul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised$30 millionSeries A funding from an international syndicate of specialist investors includingSV Health Investors,Sofinnova Partners,Longwood Fundand GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered inOxford, UK. For more information, please visitwww.sitryx.com.

AboutEliLillyand CompanyLillyis a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe,Lillyemployees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more aboutLilly, please visit us atwww.lilly.com. C-LLY

LillyForward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration betweenLillyand Sitryx, and reflectsLilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee thatLillywill realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ fromLilly's expectations, please seeLilly's most recent Forms 10-K and 10-Q filed with theU.S. Securities and Exchange Commission.Lillyundertakes no duty to update forward-looking statements.

See the original post here:
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines - PharmiWeb.com

Immunology

Heat Biologics Announces Formation of COVID-19 Advisory Board – Yahoo Finance

DURHAM, NC / ACCESSWIRE / April 1, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, announced today the formation of its COVID-19 Advisory Board (CAB) with four key appointments: Justin Stebbing MD, PhD, Raymond Pickles, PhD, Natasa Strbo MD, DSc, and Lanying Du, PhD.

Heat's COVID-19 Advisory Board was established with leading thought leaders to propel Heat's COVID-19 vaccine and COVID-19 diagnostic programs. The combined Advisory Board has expertise in areas of coronavirus and related respiratory virus biology and infection, immunotherapy, and vaccines. Heat recently announced a research collaboration with the University of Miami Miller School of Medicine to develop a vaccine leveraging Heat's proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. Under a separate collaboration with the University of Miami Miller School of Medicine, Heat also intends to develop a proprietary COVID-19 point-of-care diagnostic test.

The CAB members include:

Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We are thrilled to have attracted leading experts in immunotherapy and vaccines to support Heat as we continue to develop Heat's COVID-19 vaccine and COVID-19 diagnostic programs. We look forward to working closely with the CAB to advance our programs to help combat the current COVID-19 pandemic."

Justin Stebbing MD, PhD, is a Professor of Cancer Medicine and Oncology, Consultant Oncologist, at the Imperial College and Imperial College Healthcare NHS Trust. Professor Justin Stebbing specializes in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first-class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency program at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Professor Stebbing's original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009. Professor Stebbing has published over 600 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences.

Raymond Pickles, PhD, is an associate professor in the Department of Microbiology and Immunology within the UNC School of Medicine. His research is focused on how viruses infect the respiratory tract of humans and other animal species and why highly pathogenic viruses often result in more severe airway disease. He has 30 years of experience working with models of the respiratory tract and has used these models to understand infection outcomes with Respiratory Syncytial Virus (RSV), Adenoviruses, newly emerging avian influenza viruses, and newly emerging coronaviruses including SARS. He received his PhD from the University of Cambridge before completing Post-Doctoral Studies in the Division of Pulmonary Medicine at UNC-Chapel Hill

Natasa Strbo MD, DSc, is an assistant professor of microbiology and immunology at the University of Miami, Miller School of Medicine. Dr. Strbo is also a co-developer of Heat's gp96 platform and has spent many years advancing the platform as a vaccine against HIV and malaria. Dr. Strbo's current research is focused on devising a novel strategy for achieving as complete a protection as possible, the ultimate goal being the future development of an efficacious heat shock protein (HSP) gp96-Ig vaccine against HIV, malaria, ZIKA, CMV, COVID-19 and other emerging infectious diseases. Dr. Strbo was the recipient of a Miami CTSI KL2 Award (2013-2016) to study vaccine-induced immune responses in the reproductive tract of HIV-infected humanized mice and she was also awarded the University of Miami Glaser Award for 2016 to further develop HIV vaccine technology.

Story continues

Lanying Du, PhD, is a Member at the New York Blood Center (NYBC) and is the Head of Viral Immunology Laboratory at the Lindsley F. Kimball Research Institute of NYBC. Dr. Du's research focuses on the development of effective and safe vaccines and therapeutic agents to prevent and treat emerging and reemerging infectious diseases caused by coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and other coronaviruses with pandemic potential, influenza viruses, as well as flaviviruses, including Zika virus and dengue virus. Dr. Du's research also focuses on the study of pathogenic mechanisms of these viruses, based on which to design novel vaccines and therapeutic antibodies. Her research tools include rational design of novel vaccines and therapeutics, mRNA technology, drug screening, antibody production and evaluation.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer and other diseases using its proprietary gp96 platform to activate CD8+ "Killer" T-cells. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer with its gp96-based HS-110 therapeutic vaccine. HS-110 is the company's first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells. Heat Biologics has also launched a program in collaboration with the University of Miami to develop a vaccine designed to protect against the COVID-19 Coronavirus. Heat has numerous other pre-clinical programs at various stages of development. For more information, please visit http://www.heatbio.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements such as the support to be received by the SAB members with respect to Heat's continued development of its COVID-19 vaccine and COVID-19 diagnostic programs and advancing Heat's programs to help combat the current COVID-19 pandemic. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the contribution of the SAB, the ability of Heat together with researchers at the University of Miami to develop a proprietary COVID-19 point-of-care diagnostic test, the ability of Heat's vaccine platform to provide protection against COVID-19, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2018 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

CONTACT:

David Waldman+1 919 289 4017investorrelations@heatbio.com

SOURCE: Heat Biologics Inc.

View source version on accesswire.com: https://www.accesswire.com/583405/Heat-Biologics-Announces-Formation-of-COVID-19-Advisory-Board

Continued here:
Heat Biologics Announces Formation of COVID-19 Advisory Board - Yahoo Finance